AZN Latest News, Press Relases and Analysis

All

Press Releases

15 days ago - By: Chartmill

AstraZeneca PLC (NASDAQ:AZN): A Caviar Cruise Quality Investment

7 days ago - By: Zacks Investment Research - Mentions: PFE NVO LLY VKTX

Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?

7 days ago - By: Benzinga - Mentions: LLY NVO

Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership

8 days ago - By: Benzinga

Peering Into AstraZeneca PLC's Recent Short Interest

10 days ago - By: Zacks Investment Research - Mentions: AMAT LH RSG EME ...

Top Research Reports for AstraZeneca, RTX & Applied Materials

10 days ago - By: Zacks Investment Research - Mentions: PFE MRK ABBV

Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings

10 days ago - By: Zacks Investment Research

Here's Why Astrazeneca (AZN) is a Strong Momentum Stock

10 days ago - By: Stocktwits

AstraZeneca’s Enhertu Achieves Record Response Rate In Phase 3 Trial For Early Breast Cancer

11 days ago - By: AstraZeneca

DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option

12 days ago - By: AstraZeneca

ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial

12 days ago - By: Investor's Business Daily

AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash

12 days ago - By: AstraZeneca

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial

12 days ago - By: Zacks Investment Research

Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know

13 days ago - By: AstraZeneca

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

13 days ago - By: Zacks Investment Research - Mentions: SNY MRK

Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?

13 days ago - By: Zacks Investment Research - Mentions: JNJ PFE

Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?

13 days ago - By: AstraZeneca

IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial

13 days ago - By: AstraZeneca

IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

14 days ago - By: The Motley Fool - Mentions: LLY

2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades

15 days ago - By: Stocktwits - Mentions: DFAX QQMG

AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug

15 days ago - By: AstraZeneca

AstraZeneca unveils expanded manufacturing facility in Texas

17 days ago - By: Zacks Investment Research - Mentions: PFE LLY ABBV

AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve

17 days ago - By: Zacks Investment Research - Mentions: HSBC RIO SHEL

US-China Trade Tension Escalates: Should You Seek Refuge in UK ETFs?

17 days ago - By: AstraZeneca

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO

17 days ago - By: Zacks Investment Research - Mentions: QCOM APLD LEVI

Company News for Oct 13, 2025

20 days ago - By: Stocktwits

AstraZeneca Reportedly Nears Drug Pricing Deal With President Trump

20 days ago - By: Zacks Investment Research - Mentions: BMY MRK

Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?

21 days ago - By: Stocktwits - Mentions: DFAX QQMG

ASTRAZENECA PLC-SPONS ADR (AZN) Stock News

AZN Latest News, Press Relases and Analysis

AstraZeneca PLC (NASDAQ:AZN): A Caviar Cruise Quality Investment

Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?

Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership

Peering Into AstraZeneca PLC's Recent Short Interest

Top Research Reports for AstraZeneca, RTX & Applied Materials

Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings

Here's Why Astrazeneca (AZN) is a Strong Momentum Stock

AstraZeneca’s Enhertu Achieves Record Response Rate In Phase 3 Trial For Early Breast Cancer

DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option

ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial

AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial

Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?

Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?

IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial

IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades

AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug

AstraZeneca unveils expanded manufacturing facility in Texas

AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve

US-China Trade Tension Escalates: Should You Seek Refuge in UK ETFs?

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO

Company News for Oct 13, 2025

AstraZeneca Reportedly Nears Drug Pricing Deal With President Trump

Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?

AstraZeneca Announces $4.5B Investment In Virginia